EC17 for Intraoperative Imaging for Parathyroidectomy

Status Completed

Clinical Trial Summary

Primary hyperparathyroidism is a significant medical and public health problem in the world and affects approximately 100,000 new patients in the United States alone. If left untreated this can lead to renal stones, osteoporosis, fatigue, and depression. The best treatment for primary hyperparathyroidism is surgical parathyroidectomy. However surgical parathyroidectomy can be difficult due to the variant location of the parathyroid glands. Up to 5% of patients leave the operating room without surgical cure.

Primary hyperparathyroidism is an ideal disease to investigate intraoperative fluorescent imaging. This would allow surgeons to identify the parathyroid glands and resect the suspicious parathyroid glands. Folate receptor (FR) has been found to be over-expressed in parathyroid tissue and not thyroid issues. An ideal surgical treatment would combine FR-specific fluorescent tracers with intraoperative imaging. It is important to note that FR is expressed only in the proximal tubules of the kidneys, activated macrophages, and in the choroidal plexus. Thus, the false positive detection rate is expected to be extremely low.

A group well known to us in the Netherlands has completed a pilot study utilizing a folate-FITC conjugate in 12 patients with ovarian cancer. Another group of investigators in Mayo have subsequently performed this study on 20 more patients without any serious adverse events (personal communication). They report excellent sensitivity and specificity with this technique with only grade 1 side effects (allergic reaction). All side effects reversed when the injection was halted. Patients with a history of allergic reactions to insect bites should not participate (fluorescein is derived from the firefly insect, folate is an essential vitamin).

A fluorescent contrast agent (folate-FITC or EC17) will be used to determine if it will localize to the primary tumor nodule(s) or mass(es) of patients undergoing parathyroid surgery.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01996072
Study type	Interventional
Source	University of Pennsylvania
Contact
Status	Completed
Phase	Phase 1
Start date	November 2013
Completion date	September 2014

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03931109` - Circulating miRNA in Primary Hyperparathyroidism
Completed	`NCT04305561` - Preoperative Localization Strategies in Primary Hyperparathyroidism	N/A
Recruiting	`NCT03052075` - Percent Change in Baseline Bone Mineral Density (BMD) After Parathyroidectomy in Patients With Primary Hyperparathyroidism
Completed	`NCT03774771` - Safety, Pharmacokinetics, and Clinical Effects of Cinacalcet (AMG 073) in Primary Hyperparathyroidism	Phase 2
Recruiting	`NCT02854345` - Preliminary Study Concerning the Validity of Parathyroid Exploration on a CZT Camera	N/A
Completed	`NCT01222026` - Systematic Treatment After Successful Surgical Treatment for Primary Hyperparathyroidism With Strontium Ranelate	Phase 4
Recruiting	`NCT00973336` - Primary Hyperparathyroidism: Does a Systematic Treatment Improve the Calcium and Bone Metabolism After Surgery?	Phase 2
Completed	`NCT01530919` - Minimally Invasive Radioguided Parathyroidectomy	N/A
Recruiting	`NCT03605472` - Comparison of Cervical Ultrasound and Echoscintigraphy for Preoperative Localization Diagnosis in Primary Hyperparathyroidism	N/A
Completed	`NCT01306656` - Vitamin D Repletion in Primary Hyperparathyroidism	Phase 4
Terminated	`NCT00961701` - Lipids Profile in Primary Hyperparathyroidism	N/A
Completed	`NCT00432939` - Primary Hyperparathyroidism: Non-classical Manifestations	N/A
Completed	`NCT00522028` - Asymptomatic Primary Hyperparathyroidism: A Prospective, Randomized Trial	N/A
Completed	`NCT03713671` - Gait and Balance Parameters Before and After Parathyroidectomy in Patients With Primary Hyperparathyroidism	N/A
Recruiting	`NCT04969926` - Natural History Study of Parathyroid Disorders
Recruiting	`NCT03039439` - Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors
Not yet recruiting	`NCT03732157` - Feasibility of Parathyroidectomy With Exploration of 4 Parathyroid Glands in Outpatients
Completed	`NCT01460030` - An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism	Phase 3
Enrolling by invitation	`NCT04085419` - Osteoporosis in Primary Hyperparathyroidism	Phase 4
Recruiting	`NCT03935984` - Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.